Dupixent nears EU approval for rare skin disease prurigo nod... Sanofi and Regeneron's Dupixent is on track to become the first targeted drug in the EU to be approved for prurigo nodularis (PN), a ...

Sanofi and Regeneron's Dupixent is on track to become the first targeted drug in the EU to be approved for prurigo nodularis (PN), a rare and highly debilitating skin disease. The EMA's human ...

PN is a chronic inflammatory skin condition causing intense itching and thickened red nodules, primarily on the arms, legs, ...